Eagle Pharmaceuticals Inc (NASDAQ:EGRX) Expected to Announce Earnings of $0.62 Per Share

Analysts predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will post earnings of $0.62 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings, with estimates ranging from $0.49 to $0.75. Eagle Pharmaceuticals posted earnings of $1.20 per share during the same quarter last year, which would suggest a negative year over year growth rate of 48.3%. The firm is expected to report its next quarterly earnings results on Thursday, February 27th.

On average, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $2.79 per share for the current financial year, with EPS estimates ranging from $2.59 to $2.99. For the next financial year, analysts forecast that the company will report earnings of $3.46 per share, with EPS estimates ranging from $2.99 to $4.17. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Tuesday, November 12th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.43 by ($0.17). Eagle Pharmaceuticals had a return on equity of 24.10% and a net margin of 19.79%. The firm had revenue of $41.10 million during the quarter, compared to the consensus estimate of $45.44 million. During the same period in the previous year, the company posted $1.18 earnings per share. The company’s revenue for the quarter was down 19.9% on a year-over-year basis.

EGRX has been the subject of a number of recent analyst reports. ValuEngine downgraded shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. TheStreet raised shares of Eagle Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Thursday, September 19th. BidaskClub downgraded shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Royal Bank of Canada reissued a “buy” rating and set a $66.00 target price on shares of Eagle Pharmaceuticals in a research report on Sunday, August 11th. Finally, Zacks Investment Research downgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $60.25.

Shares of EGRX stock opened at $58.40 on Thursday. Eagle Pharmaceuticals has a 52-week low of $36.03 and a 52-week high of $64.94. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.36 and a current ratio of 3.59. The company has a 50-day simple moving average of $60.68 and a two-hundred day simple moving average of $56.40. The company has a market capitalization of $863.34 million, a price-to-earnings ratio of 27.94 and a beta of 1.43.

In other news, Director Hudson Executive Capital Lp sold 15,437 shares of the stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $63.57, for a total transaction of $981,330.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 51,179 shares of company stock valued at $3,184,071 over the last three months. Insiders own 31.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC boosted its holdings in Eagle Pharmaceuticals by 2.5% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,677 shares of the specialty pharmaceutical company’s stock worth $483,000 after buying an additional 214 shares during the period. US Bancorp DE boosted its holdings in Eagle Pharmaceuticals by 5.4% in the 2nd quarter. US Bancorp DE now owns 8,269 shares of the specialty pharmaceutical company’s stock worth $460,000 after buying an additional 427 shares during the period. Strs Ohio boosted its holdings in Eagle Pharmaceuticals by 4.2% in the 2nd quarter. Strs Ohio now owns 12,400 shares of the specialty pharmaceutical company’s stock worth $690,000 after buying an additional 500 shares during the period. Northern Trust Corp boosted its holdings in Eagle Pharmaceuticals by 0.4% in the 2nd quarter. Northern Trust Corp now owns 145,597 shares of the specialty pharmaceutical company’s stock worth $8,106,000 after buying an additional 529 shares during the period. Finally, State of Tennessee Treasury Department boosted its holdings in Eagle Pharmaceuticals by 7.3% in the 3rd quarter. State of Tennessee Treasury Department now owns 8,098 shares of the specialty pharmaceutical company’s stock worth $458,000 after buying an additional 552 shares during the period. 98.07% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

See Also: Average Daily Trade Volume – What It Means In Stock Trading

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.